While RUNX1 mutations are considered rather rare in BPDCN we observed eleven cases, however, most of these (nine out of eleven) where these mutations were subclonal events and some cases even exhibited syn- and/or metachronous myeloid neoplasms other than BPDCN. This evidence concerns the gene RUNX1 and CD4+/CD56+ hematodermic neoplasm.